The propensity for granzymes to limit cell longevity is underlined by the finding that GzmB−/− CD8+ T-cells have enhanced anti-leukemia activity in pre-clinical models as a result of their being better able to persist to use IFN-γ and FAS-ligand to neutralize cancer cells [17]. This evidence concerns the gene CD8A and cancer.